J&J/Jomed
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson issues non-exclusive license to Swiss firm Jomed related to certain intellectual property for balloon catheters used in coronary and peripheral procedures. Royalty payments are not being disclosed. The pact will allow Jomed to supply angioplasty and stent delivery catheters "based on a single platform technology," Jomed explains in a Nov. 20 release. A related U.S. launch is slated for the first half of 2002...
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.